Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Treatment of postmenopausal osteoporosis with parathyroid hormone decreases the risk of vertebral and nonvertebral fractures; increases vertebral, femoral, and total-body bone mineral density; and is well tolerated.
Vertebral fracture assessment using a semiquantitative technique
- H. Genant, Chun-Ying Wu, C. V. van Kuijk, M. Nevitt
- MedicineJournal of Bone and Mineral Research
- 1 September 1993
The semiquantitative approach can be applied reliably in vertebral fracture assessment when performed using well‐defined criteria, and this approach was compared with a quantitative morpho‐metric approach.
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
This newer evidence suggests that AFFs are stress or insufficiency fractures, and studies with radiographic review consistently report significant associations between A FFs and BP use, although the strength and magnitude of effect vary.
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
- D. Black, S. Cummings, K. Ensrud
- MedicineThe Lancet
- 7 December 1996
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
- P. Meunier, C. Roux, J. Reginster
- MedicineNew England Journal of Medicine
- 29 January 2004
Treatment of postmenopausal osteoporosis with strontium ranelate leads to early and sustained reductions in the risk of vertebral fractures.
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial
- B. Ettinger, D. Black, P. Lips
- Medicine
- 2000
It is indicated that raloxifene treatment over 3 years not only preserves bone mass but also lowers the risk of new vertebral fractures in postmenopausal women with osteoporosis, regardless of whether they have had fractures before starting treatment.
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT)…
- S. T. Harris, N. Watts, P. Miller
- MedicineJAMA
- 13 October 1999
The data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis.
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
Given the relative rarity of atypical femoral fractures, the task force recommends that specific diagnostic and procedural codes be created and that an international registry be established to facilitate studies of the clinical and genetic risk factors and optimal surgical and medical management of these fractures.
Cortical and Trabecular Bone Mineral Loss From the Spine and Hip in Long‐Duration Spaceflight
- T. Lang, A. Leblanc, H. Evans, Ying Lu, H. Genant, Alice Yu
- Biology, MedicineJournal of Bone and Mineral Research
- 1 June 2004
Cortex and trabecular bone loss using QCT of the spine and hip in 14 crewmembers making 4‐ to 6‐month flights on the International Space Station showed no compartment‐specific loss of bone in the spine.
Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis.
- C. Peterfy, A. Guermazi, H. Genant
- MedicineOsteoarthritis and Cartilage
- 1 March 2004
...
...